Statistics regarding the current opioid crisis in the U.S. continue to indicate cause for alarm in comparison to previous years. According to the National Institute of Drug Abuse, a subset of the U.S. National Institutes of Health (NIH), an estimated 115 people in the U.S. die every day from opioid-related overdoses as of March 2018. […]
In the healthcare industry, missing a new regulation or alternative treatment could cost you more than money or time. In order to stay informed, we’ve rounded up the most recent updates: New Non-Opioid Treatments For Opiate Withdrawal In response to the national opioid crisis, the FDA has recently approved two new treatments to mitigate […]
Manage specialty drug costs with these approaches.
VBP is designed to improve accountability for treatments and align patient/plan payments accordingly.
The opioid crisis continues to loom in healthcare, as more individuals become addicted to and die from lawful and illegal forms of opioids. While controlled substances such as heroin are to blame for much of the problem, prescription medications are also a contributor. Variation in how physicians treat chronic pain and non-nerve-related back pain and […]
Prescription drug coverage is changing in 2017, with new specific rules for the exceptions process. Take a look at our latest infographic to find out how the exceptions process may affect your prescription!
AMR’s latest infographic looks at the both the benefits and concerns of Biosimilar drugs.
In the U.S., prescriptions for and sales of opioid painkillers have nearly quadrupled since 1999, according to the Centers for Disease Control and Prevention. Researchers from the University of Michigan Medical School and the Department of Veterans Affairs’ Ann Arbor Healthcare System published a new study in the online journal Medical Care exposing a major […]
The U.S. Food and Drug Administration has a rigorous drug approval method, but recent years have shown that even this thorough process undergoes certain trends. Each year more new drug applications (NDA) are submitted and approved, including specialty drugs. The annual increase in the approval rates of novel and specialty drugs may signal a general […]
We’ve become familiar, and even comfortable, with the concept of generic drugs. These medications are identical, or “bioequivalent,” to a brand-name pharmaceutical. According to the U.S. Food and Drug Administration, generics must be chemically identical to and match the branded drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended […]